Axinn Patent Attorneys Talk ACA Pushback and the BPCIA
May 4, 2020
The Center for Biosimilars
On May 4, Axinn partner Ted Mathias participated in a video interview with The Center for Biosimilars. He discussed the overall pushback to the Affordable Care Act (ACA) and what that means for the Biologics Price Competition and Innovation Act (BPCIA).
Click to access part 1, part 2, and part 3 of the interview.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
DC Bar: The DOJ's New Antitrust Whistleblower Rewards Program: An Overview and the Road Ahead
Speaking Engagement
Antitrust
Informa Antitrust Midwest 2026
Speaking Engagement
Antitrust
National LGBTQ+ Bar Association Lavender Law Conference and Career Fair 2026
Sponsorship
What’s Up? Enforcement Updates From the Middle East and Africa
Podcast
Antitrust
AHLA Annual Meeting & In-House Counsel Program
Sponsorship
Antitrust
Lexology In-Depth: Intellectual Property and Antitrust (2026)
Byline Articles
Intellectual Property
Tracking The Rare 'Quick Look' Win In FTC's Zillow-Redfin Suit
Byline Articles
Antitrust
Gleiss Lutz Annual Antitrust Law Conference
Speaking Engagement
Antitrust
What Top Law Firms Say New Lawyers Need in the AI Era
Media Mentions
What’s the Role of Communications Strategy in M&A? How Public Affairs Impacts Antitrust
Podcast
Antitrust
